Humanigen Inc  (HGEN)
Other Ticker:  
Price: $0.0002 $0.00 -83.333%
Day's High: $0.0005 Week Perf: -81.82 %
Day's Low: $ 0.00 30 Day Perf: -75 %
Volume (M): 2,064 52 Wk High: $ 0.21
Volume (M$): $ 0 52 Wk Avg: $0.07
Open: $0.00 52 Wk Low: $0.00

 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 119
 Employees -
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -54
 Cash Flow (TTM) (Millions $) -66
 Capital Exp. (TTM) (Millions $) 0

Humanigen Inc
Humanigen Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for patients with serious and life-threatening diseases. The company is dedicated to advancing its proprietary monoclonal antibody platform to create transformative treatments for various conditions, including infectious diseases and cancer. Humanigen's lead product candidate, lenzilumab, is being evaluated for its potential efficacy in treating cytokine storm, a severe immune response that can lead to respiratory failure, particularly in COVID-19 patients. Humanigen Inc. aims to leverage its scientific expertise and partnerships to make meaningful contributions to the field of healthcare and improve patient outcomes.

   Company Address: 830 Morris Turnpike Short Hills 7078 NJ
   Company Phone Number: 200-3100   Stock Exchange / Ticker: NASDAQ HGEN


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Humanigen Inc

HGEN Suffers Severe Blow during January-March 31, 2023 Period, Despite Promising Quarter

The stock market has been an intriguing subject for investors all around the world. While 2022 and the start of 2023 have been met with a few challenges due to the pandemic, there is fresh news for the first quarter of 2023 earnings season that has investors looking forward. The Humanigen Inc, which trades on the stock market, have reported some rather captivating numbers that have captured the attention of many investors.
For starters, the company reported a loss of $-0.04 per share when compared to $-0.32 from the prior year. This is a significant improvement in the right direction and shows signs of a company that understands the importance of positive growth. This is not all, the company reported a decrease in income per share, which may cause some to be apprehensive; however, when this is juxtaposed to what it was in the prior reporting period, there is an overall improvement.


Humanigen Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com